Myasthenia gravis treatment

On 31 August 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number number 398. The active ingredient is H – Val – Ile – Val – Lys – Leu – Ile – Pro – Ser – Thr – Ser – Ser – Ala – Val – Asp – Thr – Pro – Tyr – Leu – Asp – Ile – Thr – Tyr – His – Phe – Val – Ala – Gln – Arg – Leu – Pro – Leu – OH for treatment of myasthenia gravis.